Croma-Pharma Acquires Synocrom™ and Returns to Orthopaedics

Contributed by: Business Wire

Logo

Tags

Other Health

Health

Science

Pharmaceutical

Research

Orthopaedics

More Like This

Croma Skincare – Where Science Meets Skin

Croma-Pharma GmbH Announces Strategic Milestone as Novaestiq Corp. Joins Waldencast

Croma Pharma Launches AI-Driven Tech Venture to Revolutionize Aesthetic Medicine via Clinicore Platform

PR Newswire associated0

Croma-Pharma GmbH Celebrates FDA Approval of Obagi saypha® MagIQ™ in the United States

PR Newswire associated0

Contura Orthopedics Expands to Canada, Bringing Arthrosamid® to North America

PR Newswire associated0

Novaestiq Unveils Platform of Innovations; Poised to Disrupt the US Aesthetic Market

Inside the Science: New White Paper Explores the Injection Set to Redefine the Treatment of Knee Osteoarthritis & Unlock Access to Non-Surgical Options for Patients on the NHS

No serious adverse events to date in ongoing phase 1/2a clinical study of SYN321